Skip to content
MARKETS / NASDAQ / IMCC
NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · SMALL CAP

IM Cannabis Corp. IMCC

7 fiscal years on record · CAD · FY2025 reported · SEC filings only
CAD 54.7M
▲ 1.3% YoY
CAD -11.3M
CAD 4.7M
In brief

What this company does

We are an international cannabis company focused on the importation, distribution and sale of medical cannabis products to medical patients in Israel and Germany. In Israel, we import, distribute and sell cannabis to local medical patients by operating medical cannabis retail pharmacies, online platforms, distribution center and logistical hubs operating through IMC Holdings' subsidiaries. IMC has been operating through Adjupharm, its German subsidiary, since 2019. We have one wholly-owned subsidiary, I.M.C. Holdings Ltd. (referred herein as IMC Holdings), incorporated in the State of Israel.

Written from the business description in IM Cannabis Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.

Growth
CAD 54.7M
Revenue, FY2025 · full 7-year series below
Revenue CAD M Net income CAD M
FY2025 · Revenue 54.7 · Net income -11.3
20M40M-80M-160M2019202020212022202320242025
Compound annual growth
+0.2%
+28.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +28.1% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−21 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -21.2% · Net -21.5%
-100%-200%-300%2019202020212022202320242025
ROE
FY2025 · ROE -1496.2%
-500%-1000%2019202020212022202320242025

Each CAD of equity lost 1496 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow CAD M
FY2025 · FCF 4.7
2M4M-20M2019202020212022202320242025
Net buybacks CAD M Dividends CAD M
FY2021 · Dividends — · Net buybacks -197.5
-80M-160M2021

Total assetsCAD 31.7M
EquityCAD -3.7M
CashCAD 2.7M
Gross debtCAD 15.3M
Net debtCAD 12.5M
Current ratio0.67×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019
Revenue CAD B0.10.10.00.10.00.00.0
Operating income CAD B−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA CAD B···−0.0−0.0−0.0−0.0
Income tax CAD B0.0−0.00.0−0.00.00.00.0
Net income CAD B−0.0−0.0−0.0−0.2−0.0−0.0−0.0
Free cash flow CAD B0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted CAD −2.67−4.51−4.45−161.88−6.70−1.90·
Dividend / sh CAD ·······
Payout %·······
ROE %−1496.2−107.4−51.2−168.7−16.7−160.5−29.6
Shares out B0.010.000.000.000.000.000.04

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures · 5 divergences in 28 reconciliationsAUDITED

Reconciled in 2 of 19 fiscal years. 5 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 67 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures5 divergent
ActivityMedicinal Chemicals & Botanical Products
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image